Featured Research

from universities, journals, and other organizations

Single flexible sigmoidoscopy screening associated with reduced colorectal cancer

Date:
August 22, 2011
Source:
Journal of the National Cancer Institute
Summary:
A single flexible sigmoidoscopy screening between the ages of 55-64 years is associated with a lower level of colorectal cancer incidence and mortality, according to a new study.

A single flexible sigmoidoscopy screening between the ages of 55-64 years is associated with a lower level of colorectal cancer (CRC) incidence and mortality, according to a study published online August 18 in the Journal of the National Cancer Institute.

Multiple randomized controlled trials have shown that fecal occult blood testing (FOBT) in CRC screening can reduce the mortality rate of patients diagnosed with CRC. Observational studies and a prior, randomized trial from the U.K., known as SCORE have shown a reduction in incidence and mortality for cancer in the rectum and sigmoid colon (distal CRC) among patients who had undergone endoscopy, suggesting that the removal of adenomas at screening can provide long-term protection against the development of distal CRC.

To determine if single flexible sigmoidoscopy is a good preventative measure in CRC screening, the researchers, coordinated by Nereo Segnan, M.D., of the Epidemiology Unit at S. Giovanni University Hospital in Turin, Italy, mailed a questionnaire investigating about subject's interest in FS screening to a random population sample of men and women between the ages of 55-64 years. Eligible interested responders were randomly assigned to either the control group (N= 17148 -- no further contact) or intervention group (N=17144 -- invitation for flexible sigmoidoscopy)

Flexible sigmoidoscopy was performed on 9,911 subjects, and of those, 9,387 (94.71%) were discharged, 55 (0.55%) were referred for surgery, 395 for follow-up surveillance colonoscopy, and the remaining 74 patients did not comply with the recommended total colonoscopy assessment.

The median follow-up period was 10.5 years for CRC incidence and 11.4 years for all-cause and CRC-specific mortality. During this period 557 people (including those detected at initial screening) were diagnosed with a CRC and 148 died of the disease.

The researchers found that in the intent-to-treat analysis, CRC incidence and mortality were reduced by 18% and 22%, respectively. CRC incidence was reduced by 31% among those who were screened (per -protocol analysis), and by 46% for advanced CRC cases.

Furthermore, CRC mortality was statistically significantly reduced by 38% in screened subjects compared to the control group.

The authors write that the reported findings, which are consistent with the observed reduction of CRC incidence and mortality among people screened in the recently published UK Flexible Sigmoidoscopy Screening Trial, support the hypothesis that "Flexible sigmoidoscopy screening offered just once represents a safe and effective method for CRC screening and ensures a long lasting reduction of CRC risk." According to the researchers, "A longer follow-up is needed to fully assess the impact on mortality and to estimate the duration of the protective effect."

In an accompanying editorial, Timothy R. Church, Ph.D., of the University of Minnesota, writes about what the best approach to CRC screenings may be. Underlying the three main CRC tests (flexible sigmoidoscopy, FOBT, and colonoscopy), Church mentions that a cost-effective analysis is an important factor in determining the best available method, stating, "these costs are driven by not only the up-front infrastructure costs for laboratories, equipment, endoscopy facilities, training, and manufacturing but also by the rates of false-positive results."

Church argues that since none of the standard three approaches to CRC screening is more effective than the other, until more substantial evidence is collected, endorsing all three methods is the best way to attack CRC. In the event of conflicting results from the tests, Church writes: "Any concerns about the potential confusion that arises from multiple approaches may be balanced by the advantages of tailoring screening to the preferences of the patient."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Single flexible sigmoidoscopy screening associated with reduced colorectal cancer." ScienceDaily. ScienceDaily, 22 August 2011. <www.sciencedaily.com/releases/2011/08/110818190553.htm>.
Journal of the National Cancer Institute. (2011, August 22). Single flexible sigmoidoscopy screening associated with reduced colorectal cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/08/110818190553.htm
Journal of the National Cancer Institute. "Single flexible sigmoidoscopy screening associated with reduced colorectal cancer." ScienceDaily. www.sciencedaily.com/releases/2011/08/110818190553.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins